Puma Biotechnology Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Puma Biotechnology in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" Puma Biotechnology stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PBYI, but not buy additional shares or sell existing shares.
View analyst ratings for Puma Biotechnology or view top-rated stocks.

3 analysts have issued 12-month target prices for Puma Biotechnology's stock. Their PBYI stock forecasts range from $6.00 to $12.00. On average, they anticipate Puma Biotechnology's share price to reach $9.25 in the next twelve months. This suggests a possible upside of 224.6% from the stock's current price.
View analysts' price targets for Puma Biotechnology or view top-rated stocks among Wall Street analysts.

Puma Biotechnology's stock was trading at $3.04 on January 1st, 2022. Since then, PBYI stock has decreased by 6.3% and is now trading at $2.85.
View the best growth stocks for 2022 here.

Puma Biotechnology is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Puma Biotechnology.

Puma Biotechnology, Inc. (NASDAQ:PBYI) posted its quarterly earnings data on Thursday, May, 5th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.05. The biopharmaceutical company had revenue of $45.70 million for the quarter, compared to the consensus estimate of $45.07 million. Puma Biotechnology had a negative trailing twelve-month return on equity of 843.16% and a negative net margin of 24.42%. The firm's quarterly revenue was down 53.5% on a year-over-year basis. During the same period last year, the company earned $0.40 earnings per share.
View Puma Biotechnology's earnings history.

Some companies that are related to Puma Biotechnology include Bicycle Therapeutics (BCYC), Altimmune (ALT), 2seventy bio (TSVT), Pharming Group (PHAR), Radius Health (RDUS), ANI Pharmaceuticals (ANIP), Kezar Life Sciences (KZR), Rani Therapeutics (RANI), Janux Therapeutics (JANX), Centessa Pharmaceuticals (CNTA), Calliditas Therapeutics AB (publ) (CALT), Amryt Pharma (AMYT), COMPASS Pathways (CMPS), Mersana Therapeutics (MRSN) and Imago BioSciences (IMGO).
View all of PBYI's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Puma Biotechnology investors own include (MDVN) (MDVN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), Dynavax Technologies (DVAX), United Airlines (UAL), (KITE) (KITE), Array Technologies (ARRY), Freeport-McMoRan (FCX) and (CELG).

Puma Biotechnology trades on the NASDAQ under the ticker symbol "PBYI."

Shares of PBYI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PBYI stock can currently be purchased for approximately $2.85.

Puma Biotechnology (NASDAQ:PBYI) has a market capitalization of $128.17 million and generates $253.20 million in revenue each year. The biopharmaceutical company earns $-29.13 million in net income (profit) each year or ($1.200010) on an earnings per share basis.

Puma Biotechnology employs 196 workers across the globe.

Puma Biotechnology's mailing address is 10880 WILSHIRE BOULEVARD SUITE 2150, LOS ANGELES CA, 90024. The official website for Puma Biotechnology is www.pumabiotechnology.com. The biopharmaceutical company can be reached via phone at (424) 248-6500, via email at [email protected], or via fax at 424-248-6501.